wu:fi20f07 antibody, wu:fi22c06 antibody, LRPAP1 antibody, DKFZp459I2430 antibody, A2MRAP antibody, A2RAP antibody, HBP44 antibody, MRAP antibody, RAP antibody, AA617339 antibody, AI790446 antibody, AU042172 antibody, C77774 antibody, alpha-2-macroglobulin receptor-associated protein-like antibody, low density lipoprotein receptor-related protein associated protein 1 antibody, LDL receptor related protein associated protein 1 antibody, LDL receptor related protein associated protein 1 L homeolog antibody, LOC100231803 antibody, lrpap1 antibody, LRPAP1 antibody, Lrpap1 antibody, lrpap1.L antibody
Background
39 kDa receptor-associated protein,A2MRAP,A2RAP,Alpha 2 macroglobulin receptor associated protein,Alpha 2 MRAP,Alpha-2-macroglobulin receptor-associated protein,Alpha-2-MRAP,AMRP,HBP44,Lipoprotein receptor associated protein,Low density lipoprotein receptor related protein associated protein 1,Low density lipoprotein receptor-related protein-associated protein 1,Low density lipoprotein related protein associated protein 1 alpha 2 macroglobulin receptor associated protein,Low density lipoprotein related protein associated protein 1,low density lipoprotein-related protein-associated protein 1 (alpha-2-macroglobulin receptor-associated protein 1),Lrpap1,MGC138272,MRAP,MYP23,RAP,Low density lipoprotein receptor-related protein associated protein 1also known asLRPAP1orRAPis a chaperoneproteinwhich in humans is encoded by the LRPAP1gene. LRPAP1 is involved with trafficking of certain members of the LDL receptor family including LRP1 and LRP2. It is a glycoprotein that binds to the alpha-2-macroglobulin receptor, as well as to other members of the low density lipoprotein receptor family. It acts to inhibit the binding of all know ligands for these receptors, and may prevent receptor aggregation and degradation in the endoplasmic reticulum, thereby acting as a molecular chaperone. It may be under the regulatory control of calmodulin, since it is able to bind calmodulin and be phosphorylated by calmodulin-dependent kinase II.